The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The potential of bispecific antibody-containing combinations in patients with B-cell lymphomas
Umberto Vitolo, MD, Candiolo Cancer Institute, Turin, Italy, discusses the promising role of bispecific antibodies in treating B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) and highlights the encouraging efficacy of these drugs when combined with other agents, such as lenalidomide. These combination therapies hold great potential, especially for frail patients or those with contraindications to chemotherapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s a good question, as there is a variety of novel treatments based on bispecific antibodies in B-cell, either DLBCL or follicular lymphoma. First I would say that bispecific antibodies are a good platform to be combined with other agents, mostly immune modulating agents, for instance, epcoritamab is combined with lenalidomide, also obinutuzumab is combined with lenalidomide for follicular lymphoma in the relapsed/refactory setting and also in first line...
That’s a good question, as there is a variety of novel treatments based on bispecific antibodies in B-cell, either DLBCL or follicular lymphoma. First I would say that bispecific antibodies are a good platform to be combined with other agents, mostly immune modulating agents, for instance, epcoritamab is combined with lenalidomide, also obinutuzumab is combined with lenalidomide for follicular lymphoma in the relapsed/refactory setting and also in first line. If you’ve seen the data about epcoritamab plus R2 in second line plus follicular lymphoma, the response rate is even higher compared to the single agent, of course the populations are different so it’s not possible to make a comparison directly but the preliminary data show about 90% of response rate with this combination and more than 70% of complete remission rate with this combination. This is not only for follicular lymphoma but also for instance in diffuse large B-cell lymphoma, in elderly patients, frail, or patients with comorbidities with some contraindication to chemotherapy, a combination approach with bispecifics and other agents could be an option for these patients to avoid chemotherapy.
Read more...
